Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levisoprenaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | MTOR | P42345 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoproterenol SCHEMBL29519146 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL4165 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL29386243 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Levisoprenaline SCHEMBL250806 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL3253794 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL4166 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL7627 | 0.98 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Levisoprenaline SCHEMBL4745572 | 0.98 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL6151626 | 0.98 | MAPT (0.97) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL3672791 | 0.98 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059259-A1 | NEW PROCESS FOR PHENYLEPHRINE AND SALBUTAMOL AND RELATED COMPOUNDS VIA ASYMETRIC TRANSFER HYDROGENATION OF UNPROTECTED AMINO KETONES | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-111836899-B | Method for producing an intermediate for the synthesis of optically active beta-amino alcohols by enzymatic reduction and synthetic intermediate | 欧伦股份公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-116898872-A | Application of roxburgh rose fruit polysaccharide in preparing medicament for preventing or treating myocardial ischemia | 中山市中医院 | 2023-10-20 | — | — | CN | disclosed |
| CN-112043835-B | Bioreversible introducing group for nitrogen and hydroxyl-containing drugs | 韩捷 | 2022-10-21 | — | — | CN | disclosed |
| CN-115038451-A | Multimodal compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115003279-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| US-11389415-B2 | Methods of regulating cannabinoid receptor activity-related disorders and diseases | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2022098861-A1 | COMPOSITIONS AND METHODS FOR PREPARING RECONSTRUCTED MULTILAYERED EPITHELIAL CELL SHEETS | The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11389415-B2 | Methods of regulating cannabinoid receptor activity-related disorders and diseases | CNR1, CNR2, GPR68 | ADRB2 73/4885ADRB1 61/4885ADRB3 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.